Of them, 25 switched to extended half-life products (16 to Eloctate and nine to Alprolix) and 33 remained on standard half-life products.Ĭompared with non-switchers, switchers were older and had more bleeding episodes in the year prior to enrolling in the study. Their study recruited 58 patients, mostly adults, at eight major hemophilia centers in Canada. They specifically focused on Eloctate and Alprolix, which “were the first and only available” in Canada from 2016 to 2018, the period reviewed. The scientists set out to evaluate if outcome measures improved in hemophilia patients who switched from standard to extended half-life products, as captured through disease-relevant questionnaires. However, “it is unclear how switches from standard to extended half-life factor affect patient-reported outcomes,” the researchers wrote.
